75
Participants
Start Date
December 1, 2022
Primary Completion Date
November 2, 2025
Study Completion Date
December 1, 2025
Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®)
arms : Pembrolizumab 400 mg every 6 weeks (Q6W), trifluridine/tipiracil at 35 or 30 mg/m2 twice daily (BID) for 5 days a week (D1-5, D8-12) with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks (Q4W)
Severance Hospital, Seoul
Severance Hospital, Seoul
Yonsei University
OTHER